These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443 [TBL] [Abstract][Full Text] [Related]
3. Are corticosteroids efficacious for preventing or treating neutralizing antibodies in multiple sclerosis patients treated with beta-interferons? A critically appraised topic. Zarkou S; Carter JL; Wellik KE; Demaerschalk BM; Wingerchuk DM Neurologist; 2010 May; 16(3):212-4. PubMed ID: 20445436 [TBL] [Abstract][Full Text] [Related]
4. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S; Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883 [TBL] [Abstract][Full Text] [Related]
5. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study. Pachner AR; Cadavid D; Wolansky L; Skurnick J Neurology; 2009 Nov; 73(18):1485-92. PubMed ID: 19884576 [TBL] [Abstract][Full Text] [Related]
6. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. Patti F; Amato MP; Filippi M; Gallo P; Trojano M; Comi GC J Neurol Sci; 2004 Aug; 223(1):69-71. PubMed ID: 15261564 [TBL] [Abstract][Full Text] [Related]
7. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis. Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439 [TBL] [Abstract][Full Text] [Related]
8. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis. Vartanian T; Sölberg Sørensen P; Rice G J Neurol; 2004 Jun; 251 Suppl 2():II25-30. PubMed ID: 15264109 [TBL] [Abstract][Full Text] [Related]
9. The argument against the use of cyclophosphamide and mitoxantrone in the treatment of multiple sclerosis. Jeffery DR J Neurol Sci; 2004 Aug; 223(1):41-6. PubMed ID: 15261559 [TBL] [Abstract][Full Text] [Related]
11. [Interferon-beta treatment for multiple sclerosis and predictors of response]. Kohriyama T; Ochi K; Matsumoto M Nihon Rinsho; 2008 Jun; 66(6):1119-26. PubMed ID: 18540357 [TBL] [Abstract][Full Text] [Related]
12. Management of worsening multiple sclerosis with mitoxantrone: a review. Fox EJ Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460 [TBL] [Abstract][Full Text] [Related]
13. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis. Ravnborg M; Bendtzen K; Christensen O; Jensen PE; Hesse D; Tovey MG; Sørensen PS Mult Scler; 2009 Mar; 15(3):323-8. PubMed ID: 19028832 [TBL] [Abstract][Full Text] [Related]
14. Implications of neutralising antibodies on therapeutic efficacy. Bertolotto A J Neurol Sci; 2009 Feb; 277 Suppl 1():S29-32. PubMed ID: 19200862 [TBL] [Abstract][Full Text] [Related]
15. Rationale for the use of mitoxantrone in multiple sclerosis. Edan G; Morrissey S; Le Page E J Neurol Sci; 2004 Aug; 223(1):35-9. PubMed ID: 15261558 [TBL] [Abstract][Full Text] [Related]
16. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959 [TBL] [Abstract][Full Text] [Related]